StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)

Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%

Latigo Biotherapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

No ebitda figures for Latigo Biotherapeutics

Latigo Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Latigo Biotherapeutics figures

See a number that looks wrong?